Dupixent® and Cutaneous T-Cell Lymphoma Lawsuits
Sullivan Papain Block McManus Coffinas & Cannavo P.C. is currently investigating potential lawsuits on behalf of individuals who developed cutaneous T-cell lymphoma (CTCL) after using Dupixent® (dupilumab)
Get Legal Help Now
Dupixent Lawsuits
Sullivan Papain Block McManus Coffinas & Cannavo P.C. is currently investigating potential lawsuits on behalf of individuals who developed cutaneous T-cell lymphoma (CTCL) after using Dupixent® (dupilumab) — a popular biologic medication manufactured by Sanofi and Regeneron.
Dupixent is approved to treat several chronic inflammatory and allergic conditions, including:
- Atopic dermatitis (eczema)
- Asthma
- Chronic rhinosinusitis with nasal polyps (CRSwNP)
- Eosinophilic esophagitis (EoE)
- Prurigo nodularis
While Dupixent has helped many patients manage severe allergic and inflammatory diseases, emerging reports have raised serious concerns that the medication may unmask, accelerate, or increase the risk of cutaneous T-cell lymphoma — a rare but aggressive form of skin cancer.
Understanding the Concern: Dupixent and CTCL
Dupixent works by targeting and blocking specific immune system pathways involved in inflammation. However, research and post-market data suggest that this mechanism may also interfere with the body’s natural defenses against certain cancers.
Medical studies and FDA Adverse Event Reporting System (FAERS) data have identified cases where patients developed CTCL during or after Dupixent treatment. In addition, medical literature has identified instances in which dupixent may have caused CTCL to progress more rapidly than it otherwise would have.
What is Cutaneous T-Cell Lymphoma (CTCL)?
Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin’s lymphoma that primarily affects the skin but can spread to lymph nodes, blood, and internal organs.
Common subtypes include:
- Mycosis fungoides: The most common and slowest-growing form, which can cause scaly, itchy patches or plaques on the skin.
- Sézary syndrome: A more aggressive and systemic type that affects the blood and lymphatic system, often leading to widespread redness, swelling, and immune dysfunction.
CTCL is a chronic, progressive disease that often requires lifelong treatment. Advanced stages can be difficult to manage and may carry a poor prognosis.
Contact Us
The Legal Issue
Evidence from scientific literature, adverse event reports, and patient case studies has prompted growing concern about a potential link between Dupixent and CTCL.
Victims may allege that Sanofi and Regeneron:
- Failed to adequately warn patients and healthcare providers about the potential cancer risk
- Did not update the drug’s labeling to include CTCL warnings despite emerging safety signals
- Caused CTCL or the rapid progression of CTCL
As of today, Dupixent’s label does not include a cancer warning for CTCL, despite these reported associations.
Who May Qualify for a Dupixent Lawsuit?
You may be eligible to file a claim if:
- You used Dupixent for at least 3 months or longer
- You were later diagnosed with cutaneous T-cell lymphoma, mycosis fungoides, or Sézary syndrome
- You had no prior history of CTCL or other T-cell lymphoma before using Dupixent.
Even if your circumstances differ slightly, you may still have legal rights. Our team can review your situation and help determine whether you have a valid claim.
How Sullivan Papain Can Help
At Sullivan Papain Block McManus Coffinas & Cannavo P.C., we have a long track record of success in product liability and mass tort litigation, representing clients nationwide who have been harmed by dangerous or defective drugs.
When you choose our firm, you can expect:
- No upfront costs: We only collect a fee if we secure compensation for you.
- Comprehensive case evaluation: Our team carefully reviews medical records, pathology reports, and treatment timelines to build the strongest possible claim.
- National representation: We represent clients across the United States in complex pharmaceutical litigation.
Our mission is to hold negligent parties accountable and help victims and their families obtain the justice and financial recovery they deserve.